Evidence map›Paper›PMID 36469505›Full record

ArticlePloS one2022

The prevalence of SARS-CoV-2 antibodies within the community of a private tertiary university in the Philippines: A serial cross sectional study.

Lourdes Bernadette C Sumpaico-Tanchanco, Jenica Clarisse Y Sy, Angel Belle C Dy, Myla Levantino, Arianna Maever L Amit, John Wong, Kirsten Angeles, John Paul C Vergara

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Lourdes Bernadette C Sumpaico-TanchancoSchool of Medicine and Public Health, Ateneo de Manila University, Quezon City, Philippines.ORCID 0000-0002-2057-1543
Jenica Clarisse Y SySchool of Medicine and Public Health, Ateneo de Manila University, Quezon City, Philippines.ORCID 0000-0002-7725-0062
Angel Belle C DySchool of Medicine and Public Health, Ateneo de Manila University, Quezon City, Philippines.ORCID 0000-0002-5330-7327
Myla LevantinoSchool of Medicine and Public Health, Ateneo de Manila University, Quezon City, Philippines.ORCID 0000-0003-3998-2083
Arianna Maever L AmitSchool of Medicine and Public Health, Ateneo de Manila University, Quezon City, Philippines.ORCID 0000-0003-4571-400X
John WongSchool of Medicine and Public Health, Ateneo de Manila University, Quezon City, Philippines.
Kirsten AngelesSchool of Medicine and Public Health, Ateneo de Manila University, Quezon City, Philippines.
John Paul C VergaraProfessional Schools, Ateneo de Manila University, Manila, Philippines.
Ateneo de Manila University · PH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic has caused a public health emergency in all sectors of society, including universities and other academic institutions. This study determined the seroprevalence of SARS-CoV-2 antibodies among administrators, faculty, staff, and students of a private tertiary academic institution in the Philippines over a 7 month period. It employed a serial cross-sectional method using qualitative and quantitative COVID-19 antibody test kits. A total of 1,318 participants were tested, showing 47.80% of the study population yielding IgG antibodies to SARS-CoV-2 virus. A general increase in seroprevalence was observed from June to December 2021, which coincided with the vaccine roll-out of the country. All brands yielded positive antibody formation, with mRNA vaccines having higher levels than other types of vaccines. A decreasing trend in IgG reactivity was found in vaccinated individuals after 1 to 6 months of completion of the 2 doses of the COVID-19 vaccine. Where possible, IgG and T-cell reactivity and/or neutralizing capacity against SAR-CoV-2 need to be monitored regardless of vaccine brand. Together with uptake of COVID-19 vaccines and boosters, other public health interventions such as wearing of masks and regular testing need to be continued for better protection. Effective communication is also needed to inform risks associated with activities across different settings. Investments in long-term measures such as air filtration and ventilation systems, and wastewater surveillance need to be made.

Indexed as

COVID-19COVID-19 VaccinesAntibodies, ViralCross-Sectional StudiesHumansImmunoglobulin GPandemicsPhilippinesPrevalenceSARS-CoV-2Seroepidemiologic StudiesUniversitiesWastewaterWastewater-Based Epidemiological MonitoringAntibodies, ViralCOVID-19 VaccinesImmunoglobulin GWastewater

Identifiers

PMID36469505
PMCPMC9721473
OpenAlexW4311284539

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.